Donor Lymphocyte Infusion in Hematologic Malignancies—Good to be Fresh?

Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2016-02, Vol.16 (2), p.111-115
Hauptverfasser:	Hossain, Nasheed Mohammad, Klumpp, Thomas, Ulicny, John, Garner, Michael, Kropf, Patricia Lamont, Mangan, Kenneth F, Barta, Stefan Klaus, Fung, Henry C, Martin, Mary Ellen
Format:	Artikel
Sprache:	eng
Schlagworte:	Disease-Free Survival Donor lymphocyte infusion (DLI) Event-free survival Follow-Up Studies Hematologic Neoplasms - therapy Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation - methods Humans Lymphocyte Transfusion - methods Neoplasm Recurrence, Local - therapy Overall survival Persistent or relapsed disease Retrospective Studies Tissue Donors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Since its initial application in chronic myelogenous leukemia (CML), donor lymphocyte infusion (DLI) has been applied to various hematologic malignancies with varied success. A recent trend has been the shift from using fresh cells to cryopreserved cells. In a retrospective analysis of 63 patients, we found that there was no difference in outcomes based on the type of cells used for DLI. However, in a subset of 32 patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), the use of cryopreserved cells appears to have resulted in improved event-free survival (EFS) in patients who underwent myeloablative transplantation.
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2015.10.004